Table 5.
Pharmacokinetic parameters of cabazitaxel on Days 1 and 22 (cycle 1)
| |
Day 1 |
Day 22 |
||||
|---|---|---|---|---|---|---|
| Dose, mg/m2 | Patients treated/with data | Cmax,a μg/l | AUC0–t, μg.h/l | Patients treated/with data | Cmax,a μg/l | AUC0–t, μg.h/l |
| 1.5 |
1/1 |
15.5 |
17.2 |
1/1 |
13.5 |
28.2 |
| 3 |
1/1 |
41.9 |
47.1 |
1/1 |
23.0 |
102 |
| 6 |
4/3 |
31.2 ± 15.5 (50) |
89.7 ± 51.8 (58) |
4/3 |
49.4 ± 13.8 (28) |
150 ± 34 (22) |
| 8.4 |
12/11 |
71.7 ± 54.4 (76) |
144 ± 46 (32) |
11/9 |
70 ± 30.4 (43) |
190 ± 89 (47) |
| 10 |
7/4 |
102 ± 52 (51) |
153 ± 91 (60) |
4/4 |
89.3 ± 80.6 (90) |
187 ± 56 (30) |
| 12 | 6/3 | 152 ± 148 (97) | 212 ± 120 (56) | 4/2 | 84.8–480 | 145–447 |
Data are expressed as mean ± SD (CV%).
a Observed value at 5 minutes before the end of infusion except for four patients on Days 1 and for seven patients on Day 22 for whom maximal plasma concentrations were measured 20 minutes before the end of infusion.